The stock market is on a hot streak. It's about to face a huge test
Six months into President Donald Trump's second term, a quick glance at the stock market offers a reassuring picture: The S&P 500 just closed above 6,300 points for the first time ever and has notched eight record highs in the past month.
If you look at markets halfway into the year, it might be not be apparent that there has been unprecedented trade turmoil, conflict in the Middle East and relentless attacks on the Federal Reserve's independence.
The stock market and bitcoin have soared to record highs, while bonds have resumed a steady rally and volatility in oil prices has subsided. Global markets so far this year have been remarkably resilient.
The calm mood on Wall Street is an extraordinary change from early April, when the S&P 500 hit its lowest level in over a year and was on the precipice of a bear market after Trump unveiled his initial 'Liberation Day' tariffs.
'Perhaps the move by US stocks off the early-April lows is emblematic of the age-old adage about bull markets often climbing a 'wall of worry,'' Liz Ann Sonders and Kevin Gordon, investment strategists at Charles Schwab, said in a note. 'There is no shortage of things to worry about; but that's the wall markets often climb.'
Markets are floating near record highs despite underlying tariff uncertainty. While investors have begun to shrug off a myriad of concerns, US stocks are trading at historically expensive valuations as Trump's self-imposed August 1 tariff deadline approaches. As Trump presses forward with his trade war, markets' momentum will face a tariff test.
'What has held stocks aloft … is the premise that whatever tariff increases come on August 1, they will not be permanent,' Thierry Wizman, global FX and rates strategist at Macquarie Group, said in a note.
'The prospect that 'deals' will be struck thereafter remains a factor, we believe, in keeping traders from selling stocks more aggressively,' Wizman said.
Jeff Buchbinder and Adam Turnquist, strategists at LPL Financial, said in a note that the S&P 500's 'unusually sharp and swift 'V-shaped recovery'' from its low point in early April was 'one of the most powerful post-correction rebounds in stock market history.'
The ferocity of the market's recovery has raised questions about whether it is supported by fundamentals — or if underlying weakness could arise.
While the market experienced bouts of enormous volatility in recent months, stocks continue to push higher. The S&P 500 is up 5.2% since Trump took office.
Trump has acknowledged the market's rebound. The president earlier this month told NBC News that 'tariffs have been very well received,' noting that the 'stock market hit a new high.'
The 'softening' of initial tariff announcements has 'removed the worst-case scenarios' for outlooks for economic growth and inflation, investors at BlackRock said in a note, which has supported the market's rally.
Steve Sosnick, chief strategist at Interactive Brokers trading platform, told CNN that the rally has also been driven by momentum and a fear of missing out.
'Ever since the president's about-face in early April that turned the market around, a lot of money has been made basically by investors assuming that these tariffs will be postponed, renegotiated or otherwise watered down,' Sosnick said. 'And if there's a trade that works very well for people over a long period of time, they're going to keep doing it.'
Meanwhile, bitcoin last week surged to a record high above $123,000 as Republicans in Congress pressed forward with landmark legislation to regulate cryptocurrencies.
Economists at the consultancy Capital Economics said in a note that they think the 'US economy will weather the global trade war,' enabling the S&P 500 to rise further. However, they said, Trump's 'unpredictable approach' to trade and attacks on the Fed's independence could 'trigger' a downturn in stocks.
'The widespread assumption among market participants still appears to be that the president will not follow through on threats to raise tariffs much further and that Chair Powell will remain in place, but that may prove too optimistic,' they said.
The S&P 500 has not posted a gain or loss of more than 1% since June 24. It's a sign that momentum has slowed down. Bitcoin traded around $119,000 as of Tuesday.
Megan Horneman, chief investment officer at Verdence Capital Advisors, said she thinks markets might be complacent about potential risks, given stocks are historically expensive.
While stocks and bonds have emerged relatively unscathed, one outlier is the US dollar, which has continued a precipitous decline. The US dollar index, which measures the dollar's strength against six major foreign currencies, is down almost 11% since Trump took office.
Gold and silver, meanwhile, have continued to serve as hedges against Trump's trade uncertainty. The yellow and silver precious metals have soared 30% and 35% this year, respectively.
The rally in recent months has been driven by retail investors, or individuals buying their own stocks, as opposed to Wall Street institutions, according to Venu Krishna, an equity strategist at Barclays.
'Re-risking by institutional money remains muted, making it likely that retail investors were at the helm for the latest leg of the rally,' Krishna said. He estimates retail investors poured more than $50 billion into global stocks across the past month.
Investors who bought the dip when markets dropped in April have been rewarded with an extraordinary march to fresh highs. The S&P 500 has gained almost 27% since its low point in April. The tech-heavy Nasdaq Composite has soared almost 37%.
The smaller Nasdaq 100 has gone 62 days without crossing below its 20-day moving average, which is the second longest streak on record after a 77-day streak in 1999, according to Jonathan Krinsky, chief markets technician at investment firm BTIG.
And Wall Street money that has been on the sidelines has been creeping back into the market. A survey of global fund managers in July by Bank of America showed the biggest surge in 'risk appetite' on record. The survey also showed the most bullish sentiment since February.
Ethan Harris, a market watcher and former economist at Bank of America, said in a post on LinkedIn that Trump's tariff announcements could be characterized as 'Trump always tries again,' as opposed to 'Trump always chickens out.'
'His aggressive announcements are a way to test what he can 'get away with,'' Harris said. 'Hence the steady flow of new threats, partial retreats and then more threats.'
As stocks hold near record highs as Trump's trade deadline approaches, it remains to be seen whether markets will push back on the president's plan to disrupt international trade.
'The bond vigilantes may or may not have started to make a comeback this year,' Harris said. 'Will the stock market become the trade war vigilante or remain complacent?'
See Full Web Article
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Oppenheimer Predicts Up to 590% Rally for These 2 ‘Strong Buy' Stocks
There's a lot to say about the economy and markets today. Earnings season is well underway, with 317 S&P 500 companies having reported so far, and the results have been broadly encouraging – 83% have topped profit forecasts. That strength has helped drive both the S&P 500 and NASDAQ toward record highs, although August began with a pullback as investors reacted to a weaker-than-expected jobs report and the rollout of new tariffs from President Trump. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Even with those headwinds, Oppenheimer's chief investment strategist John Stoltzfus remains optimistic about the path ahead. 'This year reminds us of the classic Charles Dickens quote, 'It was the best of times, it was the worst of times.' Although much uncertainty and worry prevailed for some time both with trade policy and geopolitical events, and given the multitude of potential outcomes, we'd note that cooler heads prevailed – leading to positive outcomes at least for now. Monetary policy by the Fed has brought down the pace of inflation (if not yet to its 2% target level) without thus far causing a recession. This in our view is a substantial achievement… We are revising our year-end price target for the S&P 500 to 7,100 from 5,950,' Stoltzfus noted. That S&P target implies a gain of ~14% from current levels, a solid gain by any standard. But some stocks are going to outperform, even substantially – and Oppenheimer analysts are predicting much stronger rallies for 2 names in particular, including one with a potential upside as high as 590%. Using the TipRanks database, we've looked at the big-picture view on both of these picks, and it seems the broader Street agrees with Oppenheimer's bullish stance – both stocks hold Strong Buy consensus ratings, with forecasts pointing to potential triple-digit gains. Let's dig into what makes these high-upside picks so compelling. Climb Bio (CLYM) We'll start with Climb Bio, a biotech research firm focused on developing new treatments for immune-mediated diseases. These conditions – affecting an estimated 1 in 7 people worldwide – often stem from malfunctioning B cells, which can mistakenly attack the body's own tissues. Climb is developing therapies that target this root cause, aiming to address a range of serious and underserved diseases. The company's pipeline includes two drug candidates: its lead program, budoprutug, is currently being tested in three clinical trials and one preclinical study, while its second candidate, CLYM116, remains in preclinical development. Budoprutug is an anti-CD19 monoclonal antibody designed to deplete B cells. The drug has shown encouraging early clinical data and is now being evaluated in clinical trials across three distinct indications: primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). In pMN, a rare autoimmune kidney disorder that causes damaging protein leakage into the urine, budoprutug is entering a Phase 2 open-label, dose-ranging trial to assess safety and efficacy. This follows positive data from a small Phase 1b study, in which 3 of 5 patients who completed all four doses achieved complete remission of proteinuria. All five patients in that study experienced rapid and sustained B-cell depletion, even at the lowest tested dose of 100 mg, and no serious drug-related adverse events were reported. Meanwhile, in ITP, Climb has received FDA clearance to begin a Phase 1b/2a study, with the trial now advancing. ITP is an autoimmune disorder in which B cells produce antibodies that target and destroy platelets. Budoprutug is being tested in this setting based on its CD19-targeting mechanism, which may offer an advantage over CD20-based therapies by depleting a broader range of B-cell populations, including plasma cells that drive the underlying disease process. The drug is also being explored in SLE, a chronic autoimmune disease that can cause widespread inflammation and tissue damage across multiple organs. A Phase 1b trial has been cleared by the FDA and is set to run at ex-U.S. sites. This open-label study is designed to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and early signs of clinical efficacy. Climb's B-cell-targeted approach is supported by the well-established role these cells play in driving lupus pathogenesis. To further expand its reach, Climb is also developing a subcutaneous formulation of budoprutug, with a Phase 1 trial in healthy volunteers expected to begin by year-end. Beyond budoprutug, Climb is advancing its second candidate, CLYM116, an Fc-engineered anti-APRIL monoclonal antibody with a novel pH-dependent mechanism. Currently in preclinical development, CLYM116 is being explored as a treatment for IgA nephropathy (IgAN), a serious kidney disorder also known as Berger's disease. Climb expects to report preclinical data and submit an Investigational New Drug (IND) application or Clinical Trial Application (CTA) by year-end. With CLYM trading at $1.45, Oppenheimer analyst Leland Gershell views the stock as a high-potential opportunity, pointing to the company's advancing clinical pipeline and the therapeutic promise of budoprutug. 'We have a favorable outlook on budoprutug across its three indications in primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE)… Each of these indications has clear IgG-driven pathophysiology and significant residual unmet need, despite existing first- and second-line therapies, where budoprutug has opportunity to shine above… We see $1B+ sales potential across these indications, and a subcutaneous, potentially use-at-home version offers upside optionality… With shares reflecting little credit for the company's opportunities and cash runway into 2027, we see favorable risk-reward and encourage investors to build a position. We would expect positive results in pMN to generate considerable stock upside potential,' Gershell opined. So how much upside does Gershell see overall? The analyst rates CLYM an Outperform (i.e., Buy), with a $10 price target – implying a substantial 590% surge over the next year. (To watch Gershell's track record, click here) Supporting this optimistic outlook, CLYM has 3 recent analyst reviews on record – all unanimously positive – earning the stock a Strong Buy consensus rating. With an average price target of $9, analysts expect shares to be changing hands at ~521% premium over the next 12 months. (See CLYM stock forecast) Wave Life Sciences (WVE) The next Oppenheimer pick is Wave Life Sciences, a biotech company developing a lineup of RNA medicines through its proprietary platform, dubbed PRISM. RNA therapeutics represent a fast-growing frontier in biotechnology, and Wave is harnessing innovations in chemistry and human genetics to create targeted treatments for serious, genetically driven diseases that have historically lacked effective solutions. This ambitious vision is translating into a diverse clinical pipeline. Wave is advancing four distinct programs, each built on a separate RNA modality: WVE-006 uses RNA editing, WVE-007 employs RNA interference (RNAi), WVE-N531 leverages exon skipping, and WVE-003 utilizes allele-selective silencing. By tackling different mechanisms and indications, the company is positioning itself to address multiple areas of high unmet medical need. WVE-006 is a GalNAc-conjugated, subcutaneously delivered RNA editing oligonucleotide (AIMer) designed to treat alpha-1 antitrypsin deficiency (AATD), a genetic disorder affecting the lungs and liver. The drug is currently in the Phase 1b/2a RestorAATion-2 trial, with key clinical data from both the 200 mg single and multidose cohorts expected in the third quarter of 2025. Additional results from the 400 mg single-dose cohort are anticipated later this fall. Progress is also accelerating with WVE-007, an RNAi therapy targeting obesity. This GalNAc-siRNA candidate works by silencing the INHBE gene and has shown strong preclinical efficacy in reducing weight while preserving muscle mass. Following promising initial safety and pharmacodynamic results in Cohort 1, Wave expanded enrollment in Cohort 2 and expects data from the first two cohorts in Q4 2025, with high-dose cohort results to follow in early 2026. The third program, WVE-N531, is an exon-skipping oligonucleotide developed for Duchenne muscular dystrophy (DMD), a severe and progressive neuromuscular disorder. In a Phase 2 open-label trial, the therapy showed statistically significant and clinically meaningful improvements in Time-to-Rise, a key measure of functional strength. Wave plans to submit a New Drug Application (NDA) in 2026 to pursue accelerated approval. Rounding out the clinical pipeline is WVE-003, an allele-selective oligonucleotide designed for Huntington's disease (HD). This first-in-class candidate has demonstrated selective reduction of mutant huntingtin protein (mHTT) while preserving healthy wild-type HTT – an approach believed to protect neuronal function. A Phase 2/3 trial is in planning, with Wave aiming to submit an IND in the second half of 2025. This pipeline, and its potential for success, has caught the attention of Oppenheimer analyst Cheng Li, who writes: 'We think RNA medicine is poised to become an important therapeutic modality for future medicine, leveraging its unique target engagement mechanism compared to other modalities. The PRISM platform further enhances the potency, durability, tissue distribution, and pharmacological properties of oligonucleotides in a multimodal fashion… We are optimistic about WVE's four clinical programs, each having its own merits and collectively providing validation to the platform technology that propels a next wave of programs for high-value targets with differentiated approaches… We anticipate multiple meaningful clinical catalysts from WVE-006 for alpha1 antitrypsin deficiency (AATD) and WVE-007 for obesity, with current valuation offering a favorable risk/reward setup.' Reflecting this conviction, Li assigns WVE an Outperform (i.e., Buy) rating, along with a $24 price target that suggests shares could surge 178% over the next year. (To watch Li's track record, click here) Li's bullish stance is echoed across the Street. The stock has picked up 12 recent analyst reviews, supporting a Strong Buy consensus rating, with an 11-to-1 split favoring Buys over Holds. Shares currently trade at $8.63, and the average price target of $18.18 points to a potential upside of ~111% over the next 12 months. (See WVE stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 minutes ago
- Yahoo
Trump Media brings Truth token plans into the open in latest SEC filing
Trump Media has formally disclosed plans for a Truth-branded utility token and digital wallet in its latest Securities and Exchange Commission filing, months after first teasing the concept in a shareholder letter. The filing describes the token as part of a 'larger rewards program' integrated into a 'Truth digital wallet,' initially allowing users to pay for Truth+ subscriptions. Over time, the token could be applied to other products and services 'in the Truth ecosphere,' hinting at a broader platform-wide utility. While the company doesn't explicitly call it a cryptocurrency, the language suggests blockchain-based infrastructure is likely. The Q2 filing marks the first time the initiative has been included in public financial documents, indicating the project is now being treated as a core component of Trump Media's crypto strategy. It comes amid an aggressive and broadening digital asset pivot. In July, Trump Media deployed $2 billion into Bitcoin and Bitcoin-related securities, making it the fifth-largest public holder of the top cryptocurrency globally. The firm said it raised $2.4 billion in May via a private placement backed by institutional investors, with $1 billion now sitting in restricted cash as collateral for convertible notes, according to the filing. The company also filed for several crypto exchange-traded funds under its fintech division, including funds tied to Bitcoin, Ethereum, and a 'Crypto Blue Chip' index. Trump Media posted $2.3 million in operating cash flow, its first positive quarter, but still recorded a net loss of $20 million, driven by stock-based compensation and lingering legal fees from its 2024 SPAC merger. CEO Devin Nunes has framed the company's crypto exposure as a safeguard against what he calls 'debanking and other acts of political discrimination' by the traditional financial system. Crypto market movers Bitcoin has gained 0.1% in the past 24 hours and is trading at $113,700. Ethereum is down 0.4% in the same period to $3,470. What we're reading UK lifts ban on crypto-linked notes for retail investors after 5 years — DL News Can be dethroned? — Milk Road By Not Staying Chain-Agnostic With Base, Could Coinbase Make a Wrong Bet? — Unchained Bitcoin and Ethereum ETFs suffer second-worst day of 2025 in 'odd end' to landmark week for crypto — DL News Kyle Baird is DL News' Weekend Editor. Got a tip? Email at kbaird@ Sign in to access your portfolio

Miami Herald
7 minutes ago
- Miami Herald
Stocks will try to recover their mojo this week
So after Friday, when the all the stocks in the Standard & Poor's 500 fell an average 1% and the major averages fell more than 2% in a week, it's understandable to ask, "OK, now what?" Don't miss the move: Subscribe to TheStreet's free daily newsletter Well, there are 1,382 earnings reports to think about. There's the economy, too. And all the tariff negotiations to consider. Will there be a deal with China? Can Canada kiss and make up with the Trump administration? How about we think about only a few earnings (we'll get to them shortly) and some of the forces that may well affect markets more than we expect now. Related: Warren Buffett's stock still struggling since May peak The Standard & Poor's 500 Index managed to hit five straight new closing highs between July 21 and July 28. The index then closed lower each day for the next four days ending with Friday's bust, with the S&P 500 off 1.6% for the day. The question is if those four days of selling were one-offs. Let's look at four realities. The indexes and many stocks have been giving off signals for weeks that it was getting to be overbought. Multiples have expanded until something triggered professional money managers to decide to wait for better prices. You saw it Thursday when the Federal Reserve held rates steady and wouldn't say when a rate is coming. You saw it Friday after reports from (AMZN) and Coinbase Global (COIN) disappointed investors. Not so much because the jobs created came in less than expected. It was the huge revisions for May and June that enraged President Trump enough to fire the head of the Bureau of Labor Statistics, accusing her of cooking the data to make him look bad. (Without evidence) This is a month, which, the Stock Traders Almanac tells us, is the worst month of the year for the Dow Jones Industrial Average and second worst month for the S&P 500 and Nasdaq Composite Index. Related: Veteran trader takes hard look at Microsoft Q4 report and sends a warning They're doing back-to-school shopping. They're worried about wild fires in the West. Along the southern Atlantic and Gulf coasts, they're watching for hurricanes. China, Mexico and Canada negotiations are moving slowly. And they're starting to be a problem for many companies that can't absorb higher costs. Listen carefully when Walmart (WMT) reports earnings on Aug. 21. Last week's selloff pushed bond yields lower. Especially the 10-year Treasury note, the key determinant of mortgage rates. The rate on a 30-year mortgage was pushing toward 6.6%. Enough to save a home buyer upwards of $1,200 a year if buying a $300,000 home with 15% down. That assumes buyers and sellers can agree on prices that make sense. Did it affect stocks last week? It sure did. Shares of D.R. Horton (DHI) jumped 5.2% to $150.30 on Friday as bond yields came down. Horton, Pultegroup (PHM) , Lennar (LEN) and (NVR) were all sharply higher Friday and led the S&P 500's Consumer Discretionary Sector. The sector index was down 3.6%, partly because of Amazon's 8.3% tumble. Michael M. Santiago/Getty Images Start with Palantir (PLTR) , which reports after Monday's close. The stock fell 2.9% last week, but it is up 13.2% this quarter and 104% this year. This an artificial intelligence play. It takes lots and lots of data and makes sense of it for military and big corporate clients. Revenue estimate: Earnings of 12 cents a share, up 33%. Revenue of $939 million would be up 38%. It is a pricey stock: Its simple price earnings ratio is 674. Its forward p/e ratio is 328. More Palantir Veteran trader surprises with Palantir price target and commentsMusk moves xAI, Grok onto Palantir turfVeteran analyst sends bold message on Palantir stock targetPalantir makes surprise move into weather On the AI vein, chipmaker Advanced Micro Devices (AMD) reports after Tuesday's close. The revenue estimate is $7.4 billion, up 27.2%. Earnings are projected at 40 cents, but down 42%. Eaton Corp (ETN) , maker of important gear used in AI applications, also reports Tuesday. Related: A country is ready to scrap all visas for Americans Wednesday brings in consumer stocks, especially McDonald's (MCD) and Walt Disney Co. (DIS) . Both should have lots to say about what consumers are telling them. Neither is expected to report big earnings and revenue gains. Eli Lilly (LLY) and Gilead Sciences (GILD) lead the Thursday earnings. The former has a big weight drug Zepound with more in the pipeline. Also reporting Uber Technologies (UBER) , DoorDash (DASH) , Shopify (SHOP) and Airbnb (ABNB) . Related: Costco has a serious credit card problem The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.